Genset, a biotechnology company, was established in 1989 in Paris, France with Pascal Brandys as its first president.
[2] Genset was listed on the NASDAQ and the Paris Bourse (now NYSE Euronext) in 1996.
At that time, the company reported identifiable assets of EUR 80.9 million and had subsidiaries in the United States, Japan, Singapore, and Australia.
[4] In 1994, Genset started the first large scale program to analyze the regulatory sequences of the human genome and in 1997 also initiated the construction of a map of single nucleotide polymorphisms as a tool to accelerate the discovery of genes associated with diseases.
[7] After 2000 Genset changed its strategy to focus on drug development, leading to the departure of its president and other founders.